<DOC>
	<DOCNO>NCT02550613</DOCNO>
	<brief_summary>The purpose study explore ability integrate MRI/PET detect evaluate treatment outcome HCC patient .</brief_summary>
	<brief_title>Evaluation Treatment Response With Integrated MRI/PET Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>This study use 18F-FDG PET functional MRI ( DCE-MRI , Diffusion-weighted MRI , MR spectroscopy ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Prior Informed Consent Form 2 . At least one measurable tumor , accord RECIST version 1.1 . 3 . Age &gt; 20 year . 4 . ECOG performance status 0 1 . 5 . Life expectancy &gt; 3 month . 6 . Confirmed Diagnosis HCC 7 . Adequate renal function ( Serum creatinine â‰¦ 1.5 x upper limit normal ) . 1 . Age &lt; 20 year old 2 . Pregnancy 3 . Contraindication MRI : claustrophobia MR noncompatible device 4 . Contraindication MR contrast medium : severe adverse reaction impair renal function ( Cre &gt; 2.0 ) 5 . History malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>MR/PET , hepatocellular carcinoma , HCC</keyword>
</DOC>